Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda Files Dengue Vaccine Candidate in Europe
March 29, 2021
- EMA Accepts Regulatory Filing of Enfortumab Vedotin: Astellas/Seagen
March 29, 2021
- Astellas Sees Growth Potential for “Rx+” as Future Bread-and-Butter Biz: EVP
March 26, 2021
- Boehringer’s Japan Sales Up 5.4% in 2020 as Ofev, Jardiance Fare Well
March 25, 2021
- Kissei Launches PIII Study of Oncolytic Viral Therapy for Bladder Cancer in Japan
March 25, 2021
- Chugai Earns Japan Nod for Blood-Based Genomic Profiling Test
March 24, 2021
- Sumitomo Dainippon Aims to Overcome Latuda Patent Cliff with Sumitovant Products: CSO
March 24, 2021
- Rohto Acquires Olympus’ Regenerative Medicine Unit
March 24, 2021
- Kowa, Kitasato Institute Team Up for Research of Infectious Disease Meds; Cepharanthine for COVID-19
March 24, 2021
- Shionogi Partner BioAge Begins US PII Study for COVID-19 Drug
March 24, 2021
- Taiho Files Antiemetic Fosnetupitant for Japan Approval
March 24, 2021
- Taisho Seeks Japan Approval for Anti-TNFα Nanobody Ozoralizumab
March 23, 2021
- Otsuka Files Tolvaptan Prodrug OPC-61815 in Japan
March 23, 2021
- Daiichi Sankyo Begins Japan PI/II for mRNA COVID-19 Vaccine
March 23, 2021
- KM Biologics Kicks Off Japan PI/II for COVID-19 Vaccine
March 23, 2021
- Eisai Starts Construction of New Injectable/Research Building in Gifu Pref.
March 23, 2021
- Japan Approves 3rd CAR-T Cell Therapy, Celgene’s Breyanzi
March 23, 2021
- ASKA Aims for 70 Billion Yen Sales by FY2025 on Growth of OB-GYN, Thyroid Spaces: New Biz Plan
March 23, 2021
- Takecab OD Tablet Filed in Japan: Takeda/Otsuka
March 23, 2021
- Lenvima/Keytruda Combo Cuts Risk of Death by 38% in Endometrial Cancer
March 22, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…